Oncoliq: Test for Early Breast Cancer Detection.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04906330

Enrollment

500

Registered

2021-05-28

Start date

2021-09-01

Completion date

2025-08-01

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Liquid biopsy, breast cancer, early detection, microRNAs.

Brief summary

Oncoliq is a novel early breast cancer detection test based on liquid biopsies and microRNAs. This innovative test will allow improving the accuracy of cancer detection which will impact on health, reducing the patient mortality and health costs. To develop this test, it has been finished the preclinical PHASE I: in laboratory animals; PHASE II: exploratory clinical phase for the discovery of candidate biomarkers in breast cancer patients and PHASE III: clinical validation of biomarkers showing that Oncoliq has 91% of sensitivity. Currently it is been setting up a pilot test for breast cancer to enrol 500 woman volunteers without previous cancer diagnosis that go to the annual medical control. The results of the pilot test will give the accuracy for early breast cancer detection.

Interventions

DIAGNOSTIC_TESTOncoliq: test for early breast cancer detection.

Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

50 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Women patients performing gynecological control * Between 50-70 years old * Without personal history of oncological disease * Informed consent signed

Exclusion criteria

* Patients who don´t meet the inclusion criteria. * Active infection with SARS-CoV-2 (COVID-19).

Design outcomes

Primary

Measure	Time frame	Description
miRNA levels in plasma	Day 1	miRNA levels in plasma will be determined by RT-qPCR.

Countries

Argentina

Contacts

Primary ContactAdriana De Siervi, PhD

adrianadesiervi@gmail.com+54 911 3269-5832

Backup ContactJuana Moro, MD

morojuana@gmail.com+54 9 11 5181-3320

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026